Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:High-priority articles: Difference between revisions
Jump to navigation
Jump to search
WikiJournalClub:High-priority articles (view source)
Revision as of 14:15, 5 March 2024
, 5 March 2024no edit summary
(→Incomplete or nonexistent: REVIVE) |
No edit summary |
||
| Line 8: | Line 8: | ||
===Incomplete or nonexistent=== | ===Incomplete or nonexistent=== | ||
* 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | |||
* 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | * 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | ||
* 2023 {{create article link|STEP-HFpEF}}: GLP-1 agonist in HFpEF and obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2306963] | * 2023 {{create article link|STEP-HFpEF}}: GLP-1 agonist in HFpEF and obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2306963] | ||
* 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | * 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | ||